Literature DB >> 2123631

Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24).

L S Ehrlich1, H G Krausslich, E Wimmer, C A Carter.   

Abstract

Capsid protein (p24;CA) of human immunodeficiency virus type 1 (HIV-1) was synthesized in Escherichia coli strain BL21 (DE3) using a plasmid encoding a truncated HIV-1 gag/pol gene. The plasmid, which contained a mutation in the frameshift region, expressed viral proteinase (PR), a pol gene product, in the gag reading frame, resulting in efficient processing of mature CA and other gag-related products. The expressed CA is soluble, recognized by monoclonal antibodies directed against HIV CA and has an N-terminal sequence identical to that of CA purified from HIV. Purification was done under mild conditions where coexpressed HIV PR retained enzymatic activity. Milligram quantities of 90% pure CA protein were obtained after chromatography on DEAE cellulose followed by facilitated aggregation of the CA in the unbound fraction. The precipitated CA was readily dissolved in low ionic strength aqueous buffer. Gel exclusion chromatography results indicated that, in solution, CA existed in oligomeric form.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2123631     DOI: 10.1089/aid.1990.6.1169

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  23 in total

1.  HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes.

Authors:  L S Ehrlich; T Liu; S Scarlata; B Chu; C A Carter
Journal:  Biophys J       Date:  2001-07       Impact factor: 4.033

2.  Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein.

Authors:  L Dietrich; L S Ehrlich; T J LaGrassa; D Ebbets-Reed; C Carter
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Preparation and crystallization of a human immunodeficiency virus p24-Fab complex.

Authors:  A J Prongay; T J Smith; M G Rossmann; L S Ehrlich; C A Carter; J McClure
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1.

Authors:  K Partin; G Zybarth; L Ehrlich; M DeCrombrugghe; E Wimmer; C Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

5.  Sprouty2 regulates PI(4,5)P2/Ca2+ signaling and HIV-1 Gag release.

Authors:  Lorna S Ehrlich; Gisselle N Medina; Carol A Carter
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

6.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria.

Authors:  J Luban; C Lee; S P Goff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release.

Authors:  A Goff; L S Ehrlich; S N Cohen; C A Carter
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 9.  HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.

Authors:  Paul Spearman
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

10.  Cross-clade recognition of HIV-1 CAp24 by CD4+ T cells in HIV-1-infected individuals in Burkina Faso and Germany.

Authors:  Thomas Böhler; Vanessa Mrosek; Kerstin Müller; Paul Schnitzler; Martin Hartmann; Thierry Ouedraogo; Boubacar Coulibaly; Ali Sié; Vanda Bartonova; Denis M Tebit; Hans-Georg Kräusslich
Journal:  Open AIDS J       Date:  2009-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.